» Articles » PMID: 12393466

Clinical Impact of the Differentiation Profile Assessed by Immunophenotyping in Patients with Diffuse Large B-cell Lymphoma

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2002 Oct 24
PMID 12393466
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

To analyze the relationship between immunophenotyping profile and main clinicopathological features and outcome in diffuse large B-cell lymphoma (DLBCL), we studied 128 patients (59 men, 69 women; median age 65 years) consecutively diagnosed with de novo DLBCL in a single institution. Cells from each patient were immunostained with CD20, CD79a, CD5, CD10, bcl-6, MUM1, CD138, bcl-2, p53, p27, and Ki-67 antibodies. Four immunophenotyping profiles were distinguished according to the pattern of differentiation: germinal center-CD10(+) (GC-CD10(+); CD10(+)/Bcl-6(+)/MUM1(-)/CD138(-)), germinal center-CD10(-) (GC-CD10(-); CD10(-)/Bcl-6(+)/ MUM1(-)/CD138(-)), post-germinal center (pGC; CD10(-)/bcl-6(+/-)/ MUM1(+)/CD138(-)), and plasmablastic (CD10(-)/bcl-6(-)/MUM1(+)/CD138(+)). Rearrangement of bcl-2 was studied by polymerase chain reaction (PCR) in 57 patients. Single-antigen expression was as follows: CD5, 2%; CD10, 21%; bcl-6, 72%; MUM1, 54%; CD138, 2%; bcl-2, 59%; p53, 28%; p27, 40%. Distribution according to differentiation profiles was as follows: GC-CD10(+), 24 patients, GC-CD10-, 30 patients; pGC, 60 patients; plasmablastic, 2 patients; other patterns, 12 patients. The pGC profile was associated with primary nodal presentation and immunoblastic morphology, whereas GC-CD10(+) tumors showed disseminated disease, centroblastic morphology, bcl-2 rearrangement, and lower Ki-67 proliferative index. GC-CD10(-) patients more often presented with primary extranodal origin, early stage, normal lactic acid dehydrogenase (LDH) levels, and low or low/intermediate International Prognostic Index (IPI) scores than the others. However, no significant difference was found in terms of response or overall survival (OS) according to these profiles. Expression of bcl-2 was associated with advanced stage, high or high-intermediate IPI, and poor OS. Expression of bcl-2 maintained predictive value in multivariate analysis, with stage and LDH. In conclusion, differentiation profile was associated with particular clinicopathological features but was not essential to predicting outcome in DLBCL patients.

Citing Articles

Development and validation of a hierarchical approach for lymphoma classification using immunohistochemical markers.

Xu J, Shi Y, Cui M, Wang Y, Fan W, Yun J Cancer Med. 2024; 13(20):e70120.

PMID: 39444262 PMC: 11499568. DOI: 10.1002/cam4.70120.


Clinicopathological analysis of diffuse large B-cell lymphoma using molecular biomarkers: a retrospective analysis from 7 Hungarian centers.

Baliko A, Szakacs Z, Kajtar B, Ritter Z, Gyenesei A, Farkas N Front Oncol. 2023; 13:1224733.

PMID: 37746254 PMC: 10514474. DOI: 10.3389/fonc.2023.1224733.


Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma.

Berker N, Yegen G, Ozluk Y, Dogan O Turk J Haematol. 2023; 40(3):162-173.

PMID: 37519110 PMC: 10476251. DOI: 10.4274/tjh.galenos.2023.2023.0110.


Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma.

Ejtehadifar M, Zahedi S, Gameiro P, Cabecadas J, Gomes Da Silva M, Beck H Cells. 2023; 12(1).

PMID: 36611989 PMC: 9818977. DOI: 10.3390/cells12010196.


Development and validation of nomograms by radiomic features on ultrasound imaging for predicting overall survival in patients with primary nodal diffuse large B-cell lymphoma.

Deng H, Zhou Y, Lu W, Chen W, Yuan Y, Li L Front Oncol. 2022; 12:991948.

PMID: 36568168 PMC: 9768489. DOI: 10.3389/fonc.2022.991948.